Welcome to our dedicated page for Gyrodyne news (Ticker: GYRO), a resource for investors and traders seeking the latest updates and insights on Gyrodyne stock.
Gyrodyne, LLC (NASDAQ: GYRO) specializes in managing strategic commercial properties, including medical office parks and industrial sites in the New York metropolitan area. This news hub provides essential updates for stakeholders tracking the company's property value optimization strategies and corporate governance developments.
Investors will find authoritative information on Gyrodyne's asset management approaches, including updates on its Flowerfield industrial site and Cortlandt Manor medical park. The page aggregates official announcements regarding shareholder initiatives, financial planning strategies, and property entitlement processes.
Key content areas include corporate governance updates, real estate portfolio enhancements, and capital allocation strategies. Users can expect verified information on board compensation alignment programs, litigation developments affecting property assets, and progress reports on value creation initiatives.
Bookmark this page for structured access to Gyrodyne's operational updates and strategic announcements. Check regularly for non-speculative insights into the company's efforts to maximize asset potential while maintaining transparent shareholder communications.
Gyrodyne (NASDAQ:GYRO) has announced a significant real estate transaction as part of its strategic liquidation plan. The company's subsidiary, GSD Flowerfield, has entered into an agreement to sell a 49-acre parcel in Smithtown, New York to B2K Smithtown LLC for a purchase price ranging from $24 million to $28.74 million, with the final price estimated at $28.74 million.
The transaction has positively impacted Gyrodyne's net asset value (NAV), increasing it to approximately $32.6 million ($14.83 per share) as of June 30, 2025, representing a 6% increase from the previous quarter's NAV of $30.8 million ($14.01 per share). The property is planned for assisted living facilities development, with over 40% to be preserved as open space.
Gyrodyne, (NASDAQ: GYRO) announced a favorable ruling by the New York Supreme Court in an Article 78 Proceeding. The court dismissed a petition against Gyrodyne's eight-lot subdivision approval of its Flowerfield property, affirming that the Planning Board conducted a thorough environmental review. This decision enhances clarity for potential buyers and supports Gyrodyne's marketing efforts led by JLL Capital Markets.
Gyrodyne is now focusing on securing final approvals and conducting a national marketing campaign to sell its properties with approved entitlements, aiming to maximize shareholder value. The company owns a 63-acre site on Long Island and a medical office park in Cortlandt Manor, NY, both subject to value-enhancing entitlement plans.
Gyrodyne, LLC (NASDAQ: GYRO) received a MOD designation for its mixed-use 154,000 square foot property in Cortlandt Manor, New York, as approved by the Town's Board on March 20, 2023. This zoning reclassification paves the way for enhanced economic development, including medical infrastructure, job creation, and housing options. The property includes 150,000 square feet for medical use and 4,000 square feet for retail. Gyrodyne aims to maximize property value and seeks a timely sale with minimized risk. The MOD adoption marks an important eight-year collaboration between Gyrodyne and local authorities.
Gyrodyne, LLC (Nasdaq: GYRO) issued a letter to shareholders from CEO Gary Fitlin on January 30, 2023, highlighting the company's continued focus on real estate with medical tenants, which has resulted in $147 million returned to shareholders. The company aims to maximize property values and distribute net asset values before dissolving by the end of 2024. Gyrodyne is addressing corporate governance concerns following the 2022 Annual Meeting and has made significant progress with its properties, including the Flowerfield and Cortlandt Manor sites. The company maintains a strong balance sheet, with debt at $9.8 million and a loan-to-value ratio of 23%.
FAQ
What is the current stock price of Gyrodyne (GYRO)?
What is the market cap of Gyrodyne (GYRO)?
